Get the Stockscreener App
408.91
0.42%
-1.3286
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $408.91, with a volume of 1.37M.
It is down -0.42% in the last 24 hours and down -7.02% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$410.24
Open:
$410.09
24h Volume:
1.37M
Relative Volume:
0.53
Market Cap:
$221.12B
Revenue:
$37.30B
Net Income/Loss:
$7.80B
P/E Ratio:
28.44
EPS:
14.3793
Net Cash Flow:
$8.60B
1W Performance:
+8.54%
1M Performance:
-7.02%
6M Performance:
+16.79%
1Y Performance:
+42.43%
1-Day Range:
$404.34
$415.76
1-Week Range:
$376.08
$415.76
52-Week Range:
$269.77
$447.03
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
409.00 | 221.79B | 37.30B | 7.80B | 8.60B | 14.38 |
LLY
Lilly Eli Co
|
1,154.87 | 1.04T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
268.55 | 648.72B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
264.97 | 468.66B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
147.91 | 372.32B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
142.78 | 268.53B | 54.66B | 13.58B | 16.05B | 7.0171 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Hold |
| Mar-10-26 | Initiated | Jefferies | Hold |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Jan-20-26 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Amgen Stock Forecast: AMGN Reclaims $410 as Pipeline Catalysts Build - TradingKey
AMGN's Dazodalibep Meets Goal in Systemic Sjogren's Disease Study - Yahoo Finance
Jefferies Adjusts Amgen Price Target to $410 From $367, Maintains Hold Rating - marketscreener.com
Amgen Stock Gains After Announcing Positive Phase 3 Sjögren’s Disease Trial Results - TIKR.com
Amgen stock rises 4.34 percent as trial data lift pipeline hopes - AD HOC NEWS
Canaccord reiterates Amgen stock Hold rating on pipeline win By Investing.com - Investing.com Canada
Canaccord reiterates Amgen stock Hold rating on pipeline win - Investing.com India
Oppenheimer reiterates Amgen stock rating on positive trial data - Investing.com India
Jefferies raises Amgen stock price target on drug trial success - Investing.com India
Amgen (AMGN) Following Its Sjögren's Trial Win Through A Valuation Lens - simplywall.st
Amgen touts Phase III success in systemic Sjögren's disease - The Pharma Letter
What is changing in the investment case for Amgen (NASDAQ:AMGN)? - Kalkine Media
Amgen Inc. (NASDAQ:AMGN) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Amgen stock heads into the open after a 4.34 percent gain - AD HOC NEWS
Is Amgen Inc (AMGN) Overvalued After 4.3% Rally? GF Value Says O - GuruFocus
Better Healthcare ETF: Invesco's Biotech-Focused IBBQ vs. iShares' Broad IYH - The Motley Fool
Amgen stock surges on positive Sjögren’s trial results - Investing.com
Amgen stock ends the day 3.36 percent higher at USD 406.37 - AD HOC NEWS
Amgen’s Dazodalibep Outlook Is Brighter After First Phase III Readout - insights.citeline.com
Amgen, Vicor among market cap stock movers on Tuesday - Investing.com India
Amgen Inc. stock outperforms competitors on strong trading day - MarketWatch
Amgen Drug Meets Goals of Key Test in Common Autoimmune Disease With No Approved Meds - MedCity News
Amgen, Vicor among market cap stock movers on Tuesday By Investing.com - Investing.com Australia
Amgen reports a Phase 3 win with Sjögren’s drug candidate - BioPharma Dive
Amgen Ranks #4 on Forbes’ Most Innovative Large Companies List - Amgen
AMGN Jumps After Win In Sjögren’s Disease Trial As Citi Flags ‘Open Questions’ - Stocktwits
Amgen Hits Primary Endpoint In Sjögren's Trial, But Approval Filing Awaits Another Trial Data - Benzinga
State Street Corp Increases Position in Amgen Inc. $AMGN - MarketBeat
Amgen's autoimmune drug succeeds in late-stage trial - Reuters
Amgen (AMGN) Posted Positive Phase 3 Results In Sjögren's Disease - Yahoo Finance
Why Amgen (AMGN) Stock Is Up Today - Quiver Quantitative
Ionis, Otsuka's Phase 3 win in ALS subtype; Boehringer's up to $1B cancer deal - Endpoints News
Amgen Inc Stock (AMGN) Moved Up by 3.90% on Sep 22: Facts Behind the Movement - TradingKey
Amgen Drug May Offer Sjögren’s Patients First Effective Therapy - Bloomberg.com
Why is Amgen stock surging today? - Investing.com
Amgen posts trial win for Sjögren's disease drug (AMGN:NASDAQ) - Seeking Alpha
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE - Amgen
Amgen stock gains 1.95 percent as estimates face pressure - AD HOC NEWS
Erste Group Bank Brokers Reduce Earnings Estimates for Amgen - MarketBeat
Malay Naik Appointed Executive Director, US Brand Lead – Oncology at Amgen - hrtoday.in
Amgen stock heads into the open after a 1.95 percent gain - AD HOC NEWS
Amgen Inc Lobbyists, 2006 - OpenSecrets
Morgan Stanley flags Amgen’s edge after heart-drug rival stumbles - thestreet.com
Amgen stock ends the day 1.95 percent higher at the close - AD HOC NEWS
Veeva Expands Amgen Partnership With Global Vault CRM Rollout Plan - Yahoo Finance
The Zacks Analyst Blog Highlights AMD, Linde, Amgen and INNOVATE - Yahoo Finance
Amgen Inc Agencies, 2026 - OpenSecrets
Amgen Inc. (AMGN) Stock Analysis: Navigating Growth with a Robust Pipeline and a 2.61% Dividend Yield - DirectorsTalk Interviews
Amgen stock heads into the open after a weaker close - AD HOC NEWS
Amgen stock gains as FDA approval and price targets land - AD HOC NEWS
Nykredit A S Takes Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Amgen Inc Stock (AMGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Khosla Rachna | SVP, Business Development |
Aug 11 '26 |
Sale |
412.57 |
2,000 |
825,134 |
6,404 |
| Khosla Rachna | SVP, Business Development |
Aug 13 '26 |
Sale |
416.43 |
1,252 |
521,365 |
6,404 |
2.65%
1.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):